 |
|
South Korean actor Yoo Ah In. Photo from Instagram/actor.yooahin |
Chosun Biz reported that the home, situated in Seoul’s Itaewon district, saw its sales contract signed on Nov. 20, with the ownership transfer recently finalized. The buyer, surnamed Park and born in July 2017, paid the full transaction amount of 6.3 billion won in cash, without taking out a loan.
At the time of filing the ownership transfer with the court, the address provided for the buyer was that of Park Hwa Mok, CEO of fashion company PeacePeacestudio, and designer Lee Su Hyun, a married couple who are the representatives of the clothing brand Mardi Mercredi.
Yoo purchased the residence in 2016 for 5.8 billion won through the private agency U Company Limited. This detached house features a basement and three above-ground floors. He previously showcased this mansion on the MBC entertainment program “I Live Alone.”
Born Uhm Hong Sik, the 38-year-old actor first appeared in a TV commercial in 2003 and quickly rose to fame after starring in the TV series “Sharp” the same year. He has received several accolades, including awards from the Asian Film Awards, Fantasia International Film Festival’s Cheval Noir, two Blue Dragon Film Awards, and two Baeksang Arts Awards.
Last October, he was indicted for using propofol 181 times between 2020 and 2022, illegally obtaining sleeping pills by impersonating another person, and smoking marijuana with an acquaintance in the U.S.
On Sep. 1, the first trial court sentenced Yoo to one year in prison for habitual use of medical narcotics and acquiring sleeping pills under another person’s name, but acquitted him on charges of instructing marijuana smoking and evidence destruction due to insufficient evidence.
At the second trial on Dec. 24, the prosecution again sought a four-year prison term, matching the initial sentencing. Yoo appealed for mercy, stating: “I will make a pledge to the public. I will swear in a sacred court. I will not forget the gravity of the law and will not repeat my folly.”
The verdict for the second trial is anticipated early next year.
